Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Rating) have been given an average rating of “Moderate Buy” by the thirteen brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to […]
StockNews.com downgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a research note released on Saturday morning. MDGL has been the topic of a number of other research reports. Oppenheimer upped their target price on shares of Madrigal Pharmaceuticals from $300.00 to $350.00 in a report […]
StockNews.com lowered shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a research report report published on Saturday. MDGL has been the subject of a number of other research reports. Canaccord Genuity Group raised their price objective on Madrigal Pharmaceuticals from $296.00 to $336.00 and gave the […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) had its price target increased by Oppenheimer from $300.00 to $350.00 in a research note released on Tuesday, The Fly reports. Other equities analysts have also recently issued reports about the stock. Canaccord Genuity Group raised their price target on shares of Madrigal Pharmaceuticals from $296.00 to $336.00 and […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) had its price target hoisted by Oppenheimer from $300.00 to $350.00 in a research report sent to investors on Tuesday, The Fly reports. A number of other equities analysts also recently issued reports on MDGL. Canaccord Genuity Group increased their price target on shares of Madrigal Pharmaceuticals from $296.00 […]